Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EVGN Stock Forecast 2026-2027
$0.48
Current Price
$5.85M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EVGN Price Targets
+345.0%
To High Target of $2.15
+345.0%
To Median Target of $2.15
+345.0%
To Low Target of $2.15
EVGN Price Momentum
+17.1%
1 Week Change
-17.2%
1 Month Change
-61.9%
1 Year Change
-56.4%
Year-to-Date Change
-67.8%
From 52W High of $1.50
+30.6%
From 52W Low of $0.37
📊 TOP ANALYST CALLS
Did EVGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Evogene is one of their latest high-conviction picks.
Latest EVGN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, EVGN has a bullish consensus with a median price target of $2.15 (ranging from $2.15 to $2.15). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.48, the median forecast implies a 345.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVGN Analyst Ratings
1
Buy
0
Hold
0
Sell
EVGN Price Target Range
Low
$2.15
Average
$2.15
High
$2.15
Current: $0.48
Latest EVGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | Lake Street | Ben Klieve | Buy | Maintains | $3.50 |
| Aug 23, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Oct 2, 2023 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Aug 18, 2023 | Lake Street | Buy | Maintains | $N/A | |
| Jul 21, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| May 2, 2023 | Lake Street | Buy | Initiates | $N/A | |
| Sep 12, 2022 | Aegis Capital | Buy | Maintains | $N/A | |
| Sep 2, 2022 | Roth MKM | Buy | Maintains | $N/A | |
| Oct 8, 2021 | Roth Capital | Buy | Initiates | $N/A | |
| Jul 29, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| Dec 1, 2020 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 12, 2014 | Credit Suisse | Outperform | Maintains | $22.00 | |
| Dec 17, 2013 | Deutsche Bank | Buy | Initiates | $N/A | |
| Dec 16, 2013 | Credit Suisse | Outperform | Initiates | $N/A |
Evogene Ltd. (EVGN) Competitors
The following stocks are similar to Evogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evogene Ltd. (EVGN) Financial Data
Evogene Ltd. has a market capitalization of $5.85M with a P/E ratio of 0.3x. The company generates $1.84M in trailing twelve-month revenue with a -6.3% profit margin.
Revenue growth is -86.3% quarter-over-quarter, while maintaining an operating margin of -952.1% and return on equity of -171.8%.
Valuation Metrics
Market Cap
$5.85M
Enterprise Value
$4.35M
P/E Ratio
0.3x
PEG Ratio
0.0x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
-86.3%
Gross Margin
-627.4%
Operating Margin
-952.1%
Net Margin
-6.3%
EPS Growth
-80.5%
Financial Health
Cash/Price Ratio
+259.6%
Current Ratio
2.8x
Debt/Equity
25.4x
ROE
-171.8%
ROA
-32.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Evogene Ltd. (EVGN) Business Model
About Evogene Ltd.
What They Do
Biotechnology company developing innovative life science solutions.
Business Model
Evogene Ltd. utilizes its proprietary computational predictive biology platform to develop products for agriculture, pharmaceuticals, and industrial applications. The company collaborates with industry leaders to commercialize its discoveries, generating revenue through partnerships and the sale of enhanced agricultural and health-related products.
Additional Information
Headquartered in Rehovot, Israel, Evogene is positioned as a key player in enhancing productivity and sustainability in biotechnology. Its focus on integrating advanced algorithms and big data analytics into product development reflects its commitment to addressing critical challenges in various sectors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
52
CEO
Mr. Ofer Haviv CPA
Country
Israel
IPO Year
2010
Website
www.evogene.comEvogene Ltd. (EVGN) Latest News & Analysis
Latest News
Quick Summary
Evogene Ltd. and the Blavatnik Center for Drug Discovery have launched a joint initiative to enhance Israel's academic innovation in small-molecule drug discovery, combining infrastructure and AI capabilities.
Why It Matters
Collaboration between Evogene and BCDD enhances Israel's innovation in drug discovery, potentially increasing market competitiveness and driving stock performance for involved companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. is utilizing agentic computational systems to define clinical and biological success criteria, enhancing discovery timelines, scalability, and success rates.
Why It Matters
The integration of advanced computational systems by Evogene Ltd. enhances drug discovery efficiency, potentially leading to faster market entry and higher returns on investment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. (NASDAQ: EVGN) will present at the BIO International Convention in San Diego from June 22-25, 2026, focusing on AI-based small molecule design for pharma and agriculture.
Why It Matters
Evogene's presence at the BIO International Convention highlights its innovative capabilities in AI-driven drug and agrochemical development, potentially attracting investor interest and partnerships.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. announced successful completion of a Phase 1 clinical study for BMC128, showing a favorable safety profile and preliminary clinical activity signals.
Why It Matters
Positive Phase 1 results for BMC128 suggest potential therapeutic value, enhancing Evogene's market position and attracting investor interest in its innovative drug development efforts.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
EverGen Infrastructure Corp. (EVGN:CA) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details on earnings and projections were provided.
Why It Matters
The Q1 2026 earnings call for EverGen Infrastructure Corp. provides insights into the company's financial performance and future outlook, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. (EVGN) held its Q1 2026 earnings call, discussing financial results and strategic developments for the quarter. Further details can be found in the full transcript.
Why It Matters
Evogene Ltd.'s Q1 2026 earnings call provides insights into the company's financial health, growth potential, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About EVGN Stock
What is Evogene Ltd.'s (EVGN) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Evogene Ltd. (EVGN) has a median price target of $2.15. The highest price target is $2.15 and the lowest is $2.15.
Is EVGN stock a good investment in 2027?
According to current analyst ratings, EVGN has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVGN stock?
Wall Street analysts predict EVGN stock could reach $2.15 in the next 12 months. This represents a 345.0% increase from the current price of $0.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evogene Ltd.'s business model?
Evogene Ltd. utilizes its proprietary computational predictive biology platform to develop products for agriculture, pharmaceuticals, and industrial applications. The company collaborates with industry leaders to commercialize its discoveries, generating revenue through partnerships and the sale of enhanced agricultural and health-related products.
What is the highest forecasted price for EVGN Evogene Ltd.?
The highest price target for EVGN is $2.15 from at , which represents a 345.0% increase from the current price of $0.48.
What is the lowest forecasted price for EVGN Evogene Ltd.?
The lowest price target for EVGN is $2.15 from at , which represents a 345.0% increase from the current price of $0.48.
What is the overall EVGN consensus from analysts for Evogene Ltd.?
The overall analyst consensus for EVGN is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.15.
How accurate are EVGN stock price projections?
Stock price projections, including those for Evogene Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 3:01 AM UTC